Strategic biomarker introductions VDIs track record of developing and licensing biomarkers (NT-proBNP now CardioPet through IDEXX) indicates a proven pathway for product validation, regulatory navigation, and channel partnerships that sales teams can leverage to pursue co-development and distribution deals.

Expanded diagnostic portfolio The ongoing validation and active promotion of biomarkers for canine/feline lymphoma, hemangiosarcoma, and sepsis, plus a CLIA laboratory offering proprietary biomarkers for Multiple Sclerosis, present cross‑selling opportunities across veterinary oncology, critical care, and neurology segments.

Strategic partnerships Existing collaboration with IDEXX for CardioPet demonstrates appetite for distribution partnerships; sales efforts can target similar frontline diagnostic distributors, referral networks, and integrators to accelerate uptake of new biomarkers.

Small but agile With a compact team and a niche focus, VDI is positioned to be highly responsive in pilot programs, pilots for new biomarkers, and rapid iteration of go-to-market strategies, which can reduce sales cycle times for early adopters.

Clinical and lab synergies VDIs dual footprint in veterinary diagnostics and the CLIA‑certified Glycominds lab enables bundled offerings or companion diagnostic services for clinics, enabling higher value propositions and potential upsell to clients seeking comprehensive biomarker workflows.